Somatic mutations in the RET proto-oncogene in sporadic medullary thyroid carcinoma. 1996

D J Marsh, and D L Learoyd, and S D Andrew, and L Krishnan, and R Pojer, and A L Richardson, and L Delbridge, and C Eng, and B G Robinson
Molecular Genetics Unit, University of Sydney, NSW, Australia.

OBJECTIVE We have determined the frequency of specific mutations in the RET proto-oncogene in sporadic medullary thyroid carcinomas (MTCs) and correlated the presence or absence of a codon 918 mutation with the clinical characteristics of these tumours. METHODS Thirty paraffin-embedded sporadic MTCs and two frozen MTCs were collected for analysis of specific mutations in the RET proto-oncogene in codons 609, 611, 618 and 620 (exon 10); 630 and 634 (exon 11); 768 (exon 13); 883 (exon 15) and 918 (exon 16). A novel primer was designed which introduced a restriction site for Rsal in the presence of the specific codon 918 mutation (ATG-->ACG) in these tumour samples. A 'clinical-genetic' correlation was performed comparing the presence of absence of the codon 918 mutation with the following clinical characteristics: age at diagnosis, tumour size, presence or absence of metastases, MTC related morbidity, and base line calcitonin levels at diagnosis or most recent follow-up. METHODS Patients were classified as having sporadic MTC if there was no family history of C-cell hyperplasia, MTC, phaeochromocytoma or parathyroid disease. Retrospective review of patient records enabled complete clinical data to be obtained in 28 of 32 patients. METHODS Base line calcitonin levels were measured by radioimmunoassay or calcitonin enzyme linked immunoassay. Cysteine codons in exons 10 and 11, specifically codons 609, 611, 618, 620, 630 and 634, were screened for the presence of mutations by sequence analysis. Specific mutations occurring at codons 768, 883 and 918 were screened for by restriction endonuclease digestion of PCR products. RESULTS The mutation at codon 918ATG-->ACG was found in 21 of 32 (66%) MTCs and the mutation at codon 883GCT-->TTT was found in one of 32 MTCs. Where possible, the presence of 'germline-type' mutations in codons 609, 611, 618, 620, 630 and 634 were excluded. Ten MTCs did not have a mutation in codons 768, 883 or 918 of the RET proto-oncogene. The presence or absence of the somatic mutation at codon 918 did not correlate with any of the above clinical characteristics. CONCLUSIONS Somatic mutations in the RET protooncogene occur frequently in sporadic MTCs.

UI MeSH Term Description Entries
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D008969 Molecular Sequence Data Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories. Sequence Data, Molecular,Molecular Sequencing Data,Data, Molecular Sequence,Data, Molecular Sequencing,Sequencing Data, Molecular
D011518 Proto-Oncogene Proteins Products of proto-oncogenes. Normally they do not have oncogenic or transforming properties, but are involved in the regulation or differentiation of cell growth. They often have protein kinase activity. Cellular Proto-Oncogene Proteins,c-onc Proteins,Proto Oncogene Proteins, Cellular,Proto-Oncogene Products, Cellular,Cellular Proto Oncogene Proteins,Cellular Proto-Oncogene Products,Proto Oncogene Products, Cellular,Proto Oncogene Proteins,Proto-Oncogene Proteins, Cellular,c onc Proteins
D011519 Proto-Oncogenes Normal cellular genes homologous to viral oncogenes. The products of proto-oncogenes are important regulators of biological processes and appear to be involved in the events that serve to maintain the ordered procession through the cell cycle. Proto-oncogenes have names of the form c-onc. Proto-Oncogene,Proto Oncogene,Proto Oncogenes
D002116 Calcitonin A peptide hormone that lowers calcium concentration in the blood. In humans, it is released by thyroid cells and acts to decrease the formation and absorptive activity of osteoclasts. Its role in regulating plasma calcium is much greater in children and in certain diseases than in normal adults. Thyrocalcitonin,Calcitonin(1-32),Calcitrin,Ciba 47175-BA,Eel Calcitonin,Calcitonin, Eel,Ciba 47175 BA,Ciba 47175BA
D003062 Codon A set of three nucleotides in a protein coding sequence that specifies individual amino acids or a termination signal (CODON, TERMINATOR). Most codons are universal, but some organisms do not produce the transfer RNAs (RNA, TRANSFER) complementary to all codons. These codons are referred to as unassigned codons (CODONS, NONSENSE). Codon, Sense,Sense Codon,Codons,Codons, Sense,Sense Codons
D004252 DNA Mutational Analysis Biochemical identification of mutational changes in a nucleotide sequence. Mutational Analysis, DNA,Analysis, DNA Mutational,Analyses, DNA Mutational,DNA Mutational Analyses,Mutational Analyses, DNA
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000090063 Proto-Oncogene Mas A protein that is encoded by the MAS1 gene. It is a receptor for ANGIOTENSIN 1-7 and acts as an antagonist of ANGIOTENSIN-2 TYPE 1 RECEPTOR. C-Mas Protein,II-Proto-Oncogene Proteins, Cellular,Mas Protein,Mas1 Protein,Proto-Oncogene Protein Mas,Proto-Oncogene Proteins C-Mas-1,C Mas Protein,C-Mas-1, Proto-Oncogene Proteins,Cellular II-Proto-Oncogene Proteins,II Proto Oncogene Proteins, Cellular,Mas, Proto-Oncogene,Protein Mas, Proto-Oncogene,Protein, C-Mas,Protein, Mas,Protein, Mas1,Proteins, Cellular II-Proto-Oncogene,Proto Oncogene Mas,Proto Oncogene Proteins C Mas 1
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

D J Marsh, and D L Learoyd, and S D Andrew, and L Krishnan, and R Pojer, and A L Richardson, and L Delbridge, and C Eng, and B G Robinson
January 2001, Wiadomosci lekarskie (Warsaw, Poland : 1960),
D J Marsh, and D L Learoyd, and S D Andrew, and L Krishnan, and R Pojer, and A L Richardson, and L Delbridge, and C Eng, and B G Robinson
March 2008, Molecular and cellular endocrinology,
D J Marsh, and D L Learoyd, and S D Andrew, and L Krishnan, and R Pojer, and A L Richardson, and L Delbridge, and C Eng, and B G Robinson
October 1996, The Journal of clinical endocrinology and metabolism,
D J Marsh, and D L Learoyd, and S D Andrew, and L Krishnan, and R Pojer, and A L Richardson, and L Delbridge, and C Eng, and B G Robinson
March 2006, Thyroid : official journal of the American Thyroid Association,
D J Marsh, and D L Learoyd, and S D Andrew, and L Krishnan, and R Pojer, and A L Richardson, and L Delbridge, and C Eng, and B G Robinson
February 1998, Molecular and cellular endocrinology,
D J Marsh, and D L Learoyd, and S D Andrew, and L Krishnan, and R Pojer, and A L Richardson, and L Delbridge, and C Eng, and B G Robinson
February 1997, Deutsche medizinische Wochenschrift (1946),
D J Marsh, and D L Learoyd, and S D Andrew, and L Krishnan, and R Pojer, and A L Richardson, and L Delbridge, and C Eng, and B G Robinson
October 1994, Human molecular genetics,
D J Marsh, and D L Learoyd, and S D Andrew, and L Krishnan, and R Pojer, and A L Richardson, and L Delbridge, and C Eng, and B G Robinson
January 2007, Clinical laboratory,
D J Marsh, and D L Learoyd, and S D Andrew, and L Krishnan, and R Pojer, and A L Richardson, and L Delbridge, and C Eng, and B G Robinson
August 1997, Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen,
D J Marsh, and D L Learoyd, and S D Andrew, and L Krishnan, and R Pojer, and A L Richardson, and L Delbridge, and C Eng, and B G Robinson
October 2005, Journal of endocrinological investigation,
Copied contents to your clipboard!